Immunoprotein Diagnostic Testing Market Growth Accelerates with Precision Diagnostics

Author : ashlesha more | Published On : 06 Oct 2026

Immunoprotein Diagnostic Testing Market to Reach USD 18.38 Billion by 2034 as Advanced Immunoassays and Disease Monitoring Expand

The global immunoprotein diagnostic testing market was valued at USD 10.39 billion in 2025 and is projected to grow from USD 11.07 billion in 2026 to USD 18.38 billion by 2034, registering a CAGR of 6.54% during 2026–2034. Market growth is being supported by the rising use of immunoprotein assays in oncology, autoimmune disorders, infectious diseases, chronic inflammatory conditions, and long-term disease monitoring. North America dominated the market with a 38.5% share in 2025, while Asia Pacific is expected to record the fastest growth during the forecast period.

Market Size (2025): USD 10.39 Billion
Market Size (2026): USD 11.07 Billion
CAGR (Forecast Period): 6.54%
Forecast Year: 2034
Projected Market Size (2034): USD 18.38 Billion
Dominant Region: North America – 38.5% share in 2025
Fastest Growing Region: Asia Pacific – 8.12% CAGR during 2026–2034

Immunoprotein Diagnostic Testing Market Overview

Immunoprotein diagnostic testing uses immunological methods to detect and measure specific proteins associated with disease, immune response, inflammation, and other physiological conditions. These tests are widely used to support diagnosis, treatment selection, and ongoing patient monitoring across infectious diseases, cancer, autoimmune disorders, and other chronic conditions.

The market is gradually shifting toward more automated, high-throughput, and multiplexed testing platforms. Advanced immunoassays can measure multiple biomarkers within a single workflow, while newer analytical approaches are improving the characterization of immunoglobulins and monoclonal proteins.

Immunoprotein Diagnostic Testing Market Growth Drivers

Autoimmune disease diagnosis is supporting recurring use of immunoprotein testing because clinicians rely on immunoglobulins, complement proteins, antibodies, and inflammatory biomarkers to evaluate abnormal immune activity. Continued growth in rheumatology and immunology testing strengthens consumption of reagents, assays, and automated laboratory systems.

Chronic inflammatory conditions also support repeated diagnostic monitoring. Patients with complex long-term conditions often require regular testing to assess disease activity and treatment response, increasing recurring utilization of immunoprotein assays across hospitals and clinical laboratories.

Immunoprotein Diagnostic Testing Market Challenges

Assay standardization remains a major operational challenge because differences in antibodies, reagents, calibration procedures, and analytical platforms can create variation in measured results. Laboratories must invest in validation, quality control, and harmonization to maintain comparable results across different testing systems.

Reimbursement pressure creates additional uncertainty for diagnostic laboratories. Rising costs associated with instruments, personnel, reagents, maintenance, and quality assurance can limit margins when reimbursement rates remain constrained, making laboratories more selective about expanding advanced testing portfolios.

Immunoprotein Diagnostic Testing Market Opportunities

Testing for plasma cell disorders and monoclonal gammopathies offers a strong commercial opportunity for hospital laboratories, oncology centers, hematology clinics, reference laboratories, and diagnostic manufacturers. Specialized testing can generate revenue through immunoglobulin assays, free-light-chain testing, monoclonal protein panels, and recurring disease-monitoring programs.

Point-of-care immunoprotein testing also creates new revenue potential in decentralized clinical settings. Compact analyzers, disposable cartridges, connected diagnostic platforms, and recurring consumables can extend testing beyond centralized laboratories into community clinics, urgent-care facilities, and other outpatient environments.

Immunoprotein Diagnostic Testing Market Segment Analysis

By product type, the kits & reagents segment dominated with a 58.9% share in 2025 and is also expected to register the fastest CAGR of 7.21% during 2026–2034, supported by continuous consumption of antibodies, calibrators, controls, substrates, and assay-specific reagents.

By technology, enzyme immunoassay held a 27.8% share in 2025, while chemiluminescence assay is projected to grow at the fastest CAGR of 7.48%. By application, oncology dominated with a 27.4% share and is expected to record a 7.56% CAGR. Diagnostic laboratories led the end-user segment with a 48.7% share in 2025 and are projected to grow at a 7.14% CAGR.

Immunoprotein Diagnostic Testing Market Regional Analysis

North America dominated the immunoprotein diagnostic testing market with a 38.5% share in 2025, supported by advanced laboratory infrastructure, broad access to specialized diagnostics, and extensive use of immunoprotein assays across oncology, autoimmune, inflammatory, and chronic disease testing.

Asia Pacific is projected to be the fastest-growing region with an 8.12% CAGR during 2026–2034. Expanding laboratory capacity, healthcare infrastructure, automated immunoassay adoption, preventive care programs, and a growing older population are strengthening diagnostic testing requirements across the region.

Europe is expected to register a 6.18% CAGR, supported by established clinical laboratory networks, greater emphasis on early diagnosis, laboratory automation, and routine use of immunoglobulin and biomarker testing.

Immunoprotein Diagnostic Testing Market Competitive Landscape

The immunoprotein diagnostic testing market is moderately competitive, with established diagnostic and life-science companies focusing on assay sensitivity, automation, expanded biomarker portfolios, laboratory workflow efficiency, and broader distribution networks. Competition is increasingly shaped by high-throughput testing, advanced immunoassay technologies, and integrated diagnostic platforms.

Key market players include:

Agilent Technologies, Inc.
Thermo Fisher Scientific Inc.
PerkinElmer Inc.
Bio-Rad Laboratories, Inc.
Aurora Biomed Inc.
Tecan Trading AG
Promega Corporation
Charles River Laboratories
Creative Biolabs
ACROBiosystems
DiaSorin S.p.A.
Beckman Coulter, Inc.

Immunoprotein Diagnostic Testing Market Recent Developments

During 2025, major diagnostic companies continued advancing automated immunoassay platforms, electrochemiluminescence testing, laboratory systems, and biomarker analysis technologies. Recent development activity emphasized improved testing accuracy, faster workflows, enhanced disease monitoring, greater automation, and stronger support for personalized healthcare.

Click Here to Access the Comprehensive Report:https://straitsresearch.com/report/immunoprotein-diagnostic-testing-market

Immunoprotein Diagnostic Testing Market Future Outlook

The immunoprotein diagnostic testing market is expected to maintain steady growth through 2034 as healthcare systems place greater emphasis on early disease detection, recurring biomarker monitoring, personalized treatment, and automated laboratory workflows. Multiplex immunoassays, chemiluminescence platforms, point-of-care testing, and advanced protein analysis are likely to expand testing capabilities across both centralized and decentralized settings.

Continued improvements in assay standardization, automation, analytical sensitivity, and workflow integration will remain important for broader adoption. Growth opportunities are expected to remain strongest in oncology, autoimmune disease management, plasma cell disorders, and long-term monitoring of chronic inflammatory conditions.

About Straits Research

Straits Research is a global market intelligence and consulting company providing comprehensive market research, industry analysis, competitive intelligence, and strategic insights across major sectors worldwide. The company helps organizations understand market trends, emerging technologies, competitive landscapes, regional opportunities, and long-term growth prospects to support informed business decisions.